A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for theTreatment of Unresectable and Metastatic Conventional Chondrosarcoma
Sponsor: |
National Cancer Institute |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT2009 |
U.S. Govt. ID: |
NCT04340843 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to answer the following question: Is the combination of the drugs belinostat and SGI-110 (guadecitabine) effective at lowering the chance of your chondrosarcoma growing or spreading?
Investigator
Matthew Ingham, MD
Are you 18 years of age or older? |
Yes |
No |
Have you been diagnosed with chondrosarcoma that cannot be removed by surgery? |
Yes |
No |
Are you able to come to the clinic for 5 consecutive days each month to get treatment? |
Yes |
No |